WO1999058477A2 - Derives de n-[3-[2-[(2,3-dihydro-1h-inden-2-yl)alkylamino]-ethyl]phenyl]carboxamide, leur preparation et leur application en therapeutique - Google Patents
Derives de n-[3-[2-[(2,3-dihydro-1h-inden-2-yl)alkylamino]-ethyl]phenyl]carboxamide, leur preparation et leur application en therapeutique Download PDFInfo
- Publication number
- WO1999058477A2 WO1999058477A2 PCT/FR1999/001049 FR9901049W WO9958477A2 WO 1999058477 A2 WO1999058477 A2 WO 1999058477A2 FR 9901049 W FR9901049 W FR 9901049W WO 9958477 A2 WO9958477 A2 WO 9958477A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- dihydro
- inden
- mmol
- ethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/57—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C233/62—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/80—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
Definitions
- R ⁇ represents a group 2, 3-dihydro-1H-inconcen-2 ⁇ yl optionally substituted by one or two methoxy groups
- R 2 represents a group (Ci-C alkyl, preferably a propyl group
- R 3 represents either a (C 1 -C 6 ) alkyl group, or a phenyl group optionally substituted by one or more fluorine atoms or by one or more alkyl, methoxy, methoxymethyl, cyano, carbamoyl, phenyl, oxazol-5-yl, imidazol-1 groups -yle, (C 5 -C 6 ) cycloalkyl, pyrimidin-2-yl or furanyl, or a cyclohexyl group optionally substituted by a methoxy group, or a naphthyl group, or a furanyl or benzofuranyl group, or a pyridinyl group.
- the compounds of the invention may exist in the form of free bases or of addition salts with acids.
- the amide of general formula (IV) is obtained, the nitro group of which is reduced, for example by means of zinc powder, in a polar solvent, for example a mixture of acetic acid and water, at a temperature of 20 at 60 ° C.
- a polar solvent for example a mixture of acetic acid and water
- the amide of general formula (V) is obtained which is reduced to an amine, for example by the action of a mixed alkaline hydride such than lithium aluminum hydride, in an ethereal solvent, for example tetrahydrofuran, at a temperature of 0 to 65 ° C.
- a mixed alkaline hydride such than lithium aluminum hydride
- an ethereal solvent for example tetrahydrofuran
- the amines of general formula (II) can be prepared by methods analogous to those described in " . Med. Chem. (1980) 23 (7) 745-749 and in Can. J. Chem. (1974) 52 381-389 .
- 3-nitrobenzene acetic acid is commercially available.
- Example 1 (Compound No. 1).
- 6.2 g (166 mmol) of lithium aluminum hydride suspended in 300 ml of dry tetrahydrofuran are placed in a 1 liter three-necked flask under nitrogen, 17 g g (56 mmol) of 3-amino-N- (2,3-dihydro-1H-inden-2-yl) -N-propylbenzeneacetamide dissolved in 100 ml of dry tetrahydrofuran and the mixture is heated at reflux for 5 h.
- N- [3- [2- [(2,3-dihydro-1H-inden-2-yl) propylamino] ethyl] phenyl] benzamide hydrochloride 0.65 g (2.19 mmol) of N- [2- (3-aminophenyl) ethyl] -N-propyl - 2,3-dihydro-1H is placed in a 100 ml flask under a nitrogen atmosphere -inden-2-amine in 11 ml of dichloromethane, the solution is cooled to 0 ° C.
- the compounds of the invention have been subjected to a series of pharmacological tests which have demonstrated their advantage as substances with therapeutic activities.
- the compounds were the subject of an in vi tro study as to their affinity for the dopaminergic receptors D 3 obtained from a membrane preparation of the bovine caudate nucleus essentially as described by Schoemaker H. in Eur. J. Pharmacol. (1993) 242 R1-R2.
- the caudate nuclei of cattle (Iffa Credo, L'Arbresle, France), stored at -80 ° C, are thawed and homogenized at 4 ° C in 10 volumes of buffer (Tris 10 mM, EDTA 1 mM, pH 7.5 at 25 ° C) using a
- Polytron TM position 5, 30 s.
- the homogenate is centrifuged at 2500 g for 1 min (Sorvall TM centrifuge equipped with an SS34 rotor).
- the supernatant is recovered and centrifuged at 35,000 g for 15 min, the pellet is washed by resuspension in 10 volumes of buffer, homogenization and centrifugation, and the final pellet is suspended in 10 volumes of buffer and preincubated at 37 ° C. for 10 min.
- the homogenate is centrifuged at 35,000 g for 15 min, the pellet is resuspended in the incubation buffer, (HEPES 50 mM, EDTA 1 mM, 8-hydroxyquinoline 50 ⁇ M, ascorbic acid 0.005%, pH 7.5 to 25 ° C), at a rate of 100 mh of initial tissue per ml.
- HEPES 50 mM, EDTA 1 mM, 8-hydroxyquinoline 50 ⁇ M, ascorbic acid 0.005%, pH 7.5 to 25 ° C at a rate of 100 mh of initial tissue per ml.
- the membrane suspension (150 ⁇ l) is incubated at 23 ° C for 60 min in tubes, in the presence of 0.8 nM of [ 3 H] 7-OH-DPAT (specific activity 120-160 Ci / mmol, Amersham TM) in a final volume of 1 ml of incubation buffer containing 0.2 ⁇ M of iliprodil hydrochloride and 1 mg of bovine serum albumin, in the presence or in the absence of compound to be tested. Incubation is stopped by filtration on Brandel Harvester M-48 TM, using Whatman GF / C TM filters previously treated with bovine serum albumin (0.1% for 30 min.
- the filters are cut and then dried in an oven at 120 ° C for 10 min and the radioactivity retained on the filters is determined by liquid scintillation spectrometry. The non-specific binding is determined in the presence of 1 ⁇ M of dopamine.
- the IC 50 values of the compounds of the invention are of the order of 0.001 to 0.08 ⁇ M.
- the compounds displace the binding of a specific labeled ligand, spiperone (hereinafter referred to as "[ 3 H] spiperone” and described by Briley and Langer., Eur. J. Pharmacol. (1978) 50 283) on receptors D 2 present in the rat striatum.
- the animals used are male Sprague-Dawley rats weighing 150 to 250 g. After decapitation, the brain is removed and the striatum is excised. The tissue is ground using a Polytron TM mill in 50 volumes of 50 mM Tris-HCl buffer containing sodium chloride (120 mM), potassium chloride (5 mM) and the pH of which is adjusted to 7 , 4 (i.e. 100 mg of fresh tissue per 5 ml). The homogenized tissues are washed twice at 4 ° C., centrifuging them each time for 10 min at 40,000 ⁇ g and resuspending the pellet in fresh cooled buffer.
- the membranes are recovered by filtration on hatman GF / B TM filters which are washed with two volumes of 5 ml of ice-cold buffer.
- the filters are extracted into the scintillation liquid and the radioactivity is measured by liquid scintigraphy with an efficiency of 50 to 60%.
- the results are expressed by the IC 50 , that is to say by the concentration which inhibits 50% of the binding of [ 3 H] spiperone, calculated by a graphical or mathematical method.
- the compounds of the invention in this test, have an IC 50 of the order of 0.08 to 1 ⁇ M.
- the compounds displace the binding of a specific labeled ligand, [ 3 H] -8-hydroxy-2- (dipropylamino) tetralin (hereinafter referred to as "[ 3 H] -8-OH-DPAT" and described by Gozlan et al., Nature (1983) 305 140) on the 5-HT 1A receptors present in the rat hippocampus.
- the animals used are male Sprague-Dawley rats weighing 160 to 200 g. After decapitation, the brain is removed and the hippocampus is excised. The tissue is ground in an Ultra-Turrax Polytron TM device for 30 s at half the maximum speed in 10 volumes of 50 mM Tris buffer, pH adjusted to 7.4 with hydrochloric acid (i.e. 100 mg of fresh tissue per ml). The homogenized tissues are washed twice at 4 ° C., centrifuging them each time for 10 min at 48000 ⁇ g and resuspending the pellet in fresh cooled buffer. Finally, the last pellet is suspended in the buffer to arrive at a concentration of 50 mg of starting tissue per ml of 50 mM buffer.
- the specific binding of [ 3 H] 8-OH-DPAT is defined as the amount of radioactivity retained on the filters and which can be inhibited by co-incubation with 5-hydroxytryptamine at 10 ⁇ M.
- the specific bond represents 90% of the total radioactivity recovered on the filter.
- the percentage of inhibition of the binding with [ 3 H] 8-OH-DPAT is determined, then the concentration IC 50 , a concentration which inhibits 50% of the binding.
- the compounds of the invention, in this test, have an IC 50 of the order of 0.001 to 0.1 ⁇ M.
- the selectivities represented by the ratios CI 50 (D 2 ) / CI 50 (D 3 ), are between 10 and 150, and the specificities, represented by the ratios CI 50 (5-HT 1A ) / CI 50 (D 3 ), are between 0.3 and 20.
- the compounds of the invention can be used for the treatment of psychoses, in particular of schizophrenia (deficit form and productive form) and of acute or chronic extrapyramidal symptoms induced by neuroleptics, for the treatment various forms of anxiety, panic attacks, phobias, obsessive-compulsive disorder, for the treatment of various forms of depression, including psychotic depression, for the treatment of disorders due to abuse or withdrawal alcohol, sexual behavior disorders, eating disorders, and for the treatment of migraine.
- they can be presented in all forms suitable for their oral or parenteral administration, combined with any suitable excipients, and dosed to allow a daily dosage of 1 to 1000 mg.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU35271/99A AU3527199A (en) | 1998-05-12 | 1999-05-04 | (n)-{3-{2-{(2,3-dihydro-1(h)-inden-2-yl)alkylamino}-ethyl}ph enyl carboxamide derivatives, preparation and therapeutic applications |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9805935A FR2778658B1 (fr) | 1998-05-12 | 1998-05-12 | Derives de n-[3-[2-[(2,3-dihydro-1h-inden-2-yl)alkylamino]- ethyl] phenyl] carboxamide, leur preparation et leur application en therapeutique |
FR98/05935 | 1998-05-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO1999058477A2 true WO1999058477A2 (fr) | 1999-11-18 |
WO1999058477A3 WO1999058477A3 (fr) | 2000-01-27 |
Family
ID=9526237
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1999/001049 WO1999058477A2 (fr) | 1998-05-12 | 1999-05-04 | Derives de n-[3-[2-[(2,3-dihydro-1h-inden-2-yl)alkylamino]-ethyl]phenyl]carboxamide, leur preparation et leur application en therapeutique |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR019841A1 (fr) |
AU (1) | AU3527199A (fr) |
CO (1) | CO4810303A1 (fr) |
FR (1) | FR2778658B1 (fr) |
WO (1) | WO1999058477A2 (fr) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0532398A1 (fr) * | 1991-09-12 | 1993-03-17 | Synthelabo | Dérivés de N-(4,7-diméthoxyindan-2-yl)-1-(phénylcarbonyl)-N-propyl-pipéridine-4-méthanamine, leur préparation et leur application en thérapeutique |
US5272157A (en) * | 1990-03-07 | 1993-12-21 | Synthelabo | Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application |
-
1998
- 1998-05-12 FR FR9805935A patent/FR2778658B1/fr not_active Expired - Lifetime
-
1999
- 1999-05-04 AU AU35271/99A patent/AU3527199A/en not_active Abandoned
- 1999-05-04 WO PCT/FR1999/001049 patent/WO1999058477A2/fr active Application Filing
- 1999-05-06 AR ARP990102125A patent/AR019841A1/es unknown
- 1999-05-11 CO CO99029058A patent/CO4810303A1/es unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5272157A (en) * | 1990-03-07 | 1993-12-21 | Synthelabo | Derivatives of 4-(aminomethyl) piperidine, their preparation and their therapeutic application |
EP0532398A1 (fr) * | 1991-09-12 | 1993-03-17 | Synthelabo | Dérivés de N-(4,7-diméthoxyindan-2-yl)-1-(phénylcarbonyl)-N-propyl-pipéridine-4-méthanamine, leur préparation et leur application en thérapeutique |
Also Published As
Publication number | Publication date |
---|---|
AU3527199A (en) | 1999-11-29 |
WO1999058477A3 (fr) | 2000-01-27 |
FR2778658B1 (fr) | 2000-06-30 |
CO4810303A1 (es) | 1999-06-30 |
FR2778658A1 (fr) | 1999-11-19 |
AR019841A1 (es) | 2002-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1499589B1 (fr) | Derives de n-¬phenyl(piperidin-2-yl)methyl|benzamide, leur preparation et leur application en therapeutique | |
JP2755560B2 (ja) | 三環式ピラゾール誘導体 | |
US20040077851A1 (en) | Receptor selective cannabimimetic aminoalkylindoles | |
FR2861074A1 (fr) | Derives de n-[phenyl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique | |
FR2664592A1 (fr) | Nouveaux derives de la piperidine, de la tetrahydropyridine et de la pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
EP0307303B1 (fr) | [(Pyrimidinyl-2)-aminoalkyl]-1 pipéridines, leur préparation et leur application en thérapeutique | |
JPH08508738A (ja) | 5−ht1a及び/又は5−ht2リガンドとしてのインドール誘導体 | |
EP0302788A1 (fr) | Dérivés de [(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 9H-pyrido[3,4-b]indole, leur préparation et leur application en thérapeutique | |
FR2659323A1 (fr) | Derives de 4-(aminomethyl) piperidine, leur preparation et leur application en therapeutique. | |
EP0351255B1 (fr) | Dérivés de [(pipéridinyl-4)méthyl]-2 tétrahydro-1,2,3,4 isoquinoléine, leur préparation et leur application en thérapeutique | |
WO2008037881A2 (fr) | Derives de pyrrolizine, indolizine et quinolizine, leur preparation et leur application en therapeutique. | |
FR2791675A1 (fr) | Derives de n-[2-(4-aminophenyl) ethyl] -2,3-dihydro-1,4- benzodioxinne-2-methanamine, leur preparation et leur application en therapeutique | |
EP1021442B1 (fr) | Derives de 8-azabicyclo 3.2.1] octane-3-methanamine en tant que ligands des recepteurs de dopamine d2 et d3 et de serotonine 5ht1a et 5ht2 | |
EP0301936B1 (fr) | Dérivés de pipéridine, leur préparation et leur application en thérapeutique | |
FR2753970A1 (fr) | Derives de n-(benzothiazol-2-yl) piperidine-1-ethanamine, leur preparation et leur application en therapeutique | |
WO1999058477A2 (fr) | Derives de n-[3-[2-[(2,3-dihydro-1h-inden-2-yl)alkylamino]-ethyl]phenyl]carboxamide, leur preparation et leur application en therapeutique | |
EP0532398A1 (fr) | Dérivés de N-(4,7-diméthoxyindan-2-yl)-1-(phénylcarbonyl)-N-propyl-pipéridine-4-méthanamine, leur préparation et leur application en thérapeutique | |
FR2702211A1 (fr) | Nouveaux dérivés de la phénoxy-2 éthylamine, leur préparation et leur application en thérapeutique. | |
CA2346506C (fr) | Derives d'aryl-{4-fluoro-4-[(2-pyridin-2-yl-ethylamino)-methyl]-piperidin-1-yl}-methanone comme agonistes du recepteur 5-ht1 | |
CA2217479C (fr) | Derives de la phenoxyethylamine possedant une haute affinite pour le recepteur 5-ht1a, leur procede de preparation, leur application comme medicament et les compositions pharmaceutiques les renfermant | |
WO2010119222A1 (fr) | Derives de n-[(7-aza-bicyclo[2.2.1]hept-1-yl)-aryl-methyl]-benzamide, leur preparation et leur application en therapeutique | |
FR2750427A1 (fr) | Derives de 1-oxo-1, 2-dihydroisoquinoleine-4-propanamide, leur preparation et leur application en therapeutique | |
FR2769629A1 (fr) | Derives de 8-azabicyclo[3.2.1]octane-3-methanamine, leur preparation et leur application en therapeutique | |
FR2699533A1 (fr) | Dérivés de N-((1,4-dialkyl-6-arylpipérazine-2-yl)méthyl)benzamides. (Isomères cis et trans) Propriétés pharmacologiques et applications. | |
EP0580465A1 (fr) | Nouvelle utilisation thérapeutique d'hétérocyclyl-pipérazines comme 5-HT3 agonistes et nouveaux dérivés |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase |